Success Stories: An Associate Professor from Pakistan Secured I-140 (NIW) Approval in the Field of Biotechnology

Client’s Testimonial:

“Thank you so much. I am always indebted to the effort you have made in making it a success. I would really like to recommend this firm to every individual on the Globe for preparing and filing such cases.”

On April 8^th, 2021, we received another EB-2 NIW (National Interest Waiver) approval for an Associate Professor in the Field of Biotechnology (Approval Notice).

General Field: Biotechnology

Position at the Time of Case Filing: Associate Professor

Country of Origin: Pakistan

Approval Notice Date: April 8^th, 2021

Processing Time: 9 months, 12 days

Case Summary:

Holder of a Ph.D. in biotechnology, an associate professor hired North America Immigration Law Group to help him in filing an EB-2 NIW (National Interest Waiver) petition. Before taking our client’s case, we assessed his qualification and expertise in the field. After a complete evaluation, we confirmed the veracity of his credentials and aimed at preparing a credible case on his behalf to be represented to the USCIS. Our objective was to convince USCIS of our client’s work as a boon to both the pharmaceutical and healthcare industries in the U.S. Thus, we included the following in his petition pack:

Formerly, we detailed his proposed research, which focuses on applying phototherapeutic biotechnology approaches such as physical sensors and light-activated nanoparticles to treat cancer and infectious diseases, which has great importance because it involves the development of metal nanoparticles for application in tools used to treat diseases. We also noted that his research has been supported through funding from the Higher Education Commission of Pakistan. Such support by an international agency demonstrates the importance of his research on a global scale.
Further, we noted the 48 peer-reviewed journal articles (6 first-authored and 1 co-first-authored) and 1 book chapter he had published in the top journals in the biotechnology field, which impressively garnered 973 citations, reflecting his major influence on other scholars’ in understanding the topics relating to the field. Besides, we analyzed that many of his writings have been among the most cited in the field, suggesting both the originality and significance of his methods and results. He had been frequently invited to conduct peer reviews for prominent journals as well, and he has completed 35 peer reviews to date, further confirming his transcendent standing in his area of research.
To corroborate further, we added four letters of support, obtained by our client’s fellow experts. They provided more insights into his work. One of them stated:

“In the United States, the biopharmaceutical industry accounts for over a trillion dollars in yearly sales, of which the biotechnology sector represents a large portion. Producing large profits and occupying a key position in the United States economy, the biopharmaceutical industry is an invaluable component of the nation’s economic portfolio… [Client’s] work to develop useful devices for monitoring of cellular processes makes his experimentation vital to the continued economic stability and success of the United States medical sector. Thus, his work is highly valuable to the nation.”

We persuaded the USCIS with our petition presentation, and our client received his NIW approval within 9 months and 12 days. We truly thank him for trusting us with his EB-2 NIW petition. Also, we wish him well as he advances in his chosen field.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.